Benjamin Mizukawa

1.6k total citations
37 papers, 737 citations indexed

About

Benjamin Mizukawa is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Benjamin Mizukawa has authored 37 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 13 papers in Molecular Biology and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Benjamin Mizukawa's work include Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (11 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Benjamin Mizukawa is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (11 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Benjamin Mizukawa collaborates with scholars based in United States, Japan and Australia. Benjamin Mizukawa's co-authors include James C. Mulloy, Mark Wunderlich, Mahesh Shrestha, Fu‐Sheng Chou, Susumu Goyama, Kevin A. Link, Yi Zheng, H. Leighton Grimes, Ashish Kumar and Eric O’Brien and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Benjamin Mizukawa

37 papers receiving 733 citations

Peers

Benjamin Mizukawa
Munetake Shimabe Japan
Wendy A. Hudson United States
Yuji Nakata United States
Cyril Šálek Czechia
Yasuhiko Kamikubo Japan
Jesús Duque‐Afonso Germany
Karsten Kratz‐Albers Germany
Andrew Fong Canada
Stephanie M. Dobson Canada
R. Rossi United States
Munetake Shimabe Japan
Benjamin Mizukawa
Citations per year, relative to Benjamin Mizukawa Benjamin Mizukawa (= 1×) peers Munetake Shimabe

Countries citing papers authored by Benjamin Mizukawa

Since Specialization
Citations

This map shows the geographic impact of Benjamin Mizukawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Mizukawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Mizukawa more than expected).

Fields of papers citing papers by Benjamin Mizukawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Mizukawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Mizukawa. The network helps show where Benjamin Mizukawa may publish in the future.

Co-authorship network of co-authors of Benjamin Mizukawa

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Mizukawa. A scholar is included among the top collaborators of Benjamin Mizukawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Mizukawa. Benjamin Mizukawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
LeBlanc, Francis, Erin H. Breese, Karen Burns, et al.. (2024). Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 205(3). 1055–1066. 3 indexed citations
2.
He, Xiaofei, Isaac Park, Jiajia Zhang, et al.. (2024). GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1871(1). 167565–167565. 2 indexed citations
3.
Rubinstein, Jeremy D., et al.. (2023). Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy. Pediatric Blood & Cancer. 70(4). e30214–e30214. 2 indexed citations
4.
Rubinstein, Jeremy D., Erin H. Breese, Maureen M. O’Brien, et al.. (2023). The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and Cellular Therapy. 29(5). 311.e1–311.e7. 7 indexed citations
5.
Nayak, Ramesh C., Kyung Hee Chang, Abhishek Kumar Singh, et al.. (2022). Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nature Communications. 13(1). 3056–3056. 8 indexed citations
6.
Hegde, Shailaja, Mark Wunderlich, Marcel Buchholzer, et al.. (2021). Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 36(3). 637–647. 9 indexed citations
7.
Wunderlich, Mark, Nicole Manning, Eric O’Brien, et al.. (2021). PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11. 642466–642466. 17 indexed citations
8.
Rubinstein, Jeremy D., Rachana Shah, Erin H. Breese, et al.. (2021). Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective. Pediatric Blood & Cancer. 68(8). e29126–e29126. 4 indexed citations
9.
He, Xiaofei, Saran Feng, Jiajia Zhang, et al.. (2020). Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. Experimental Hematology. 86. 21–27.e2. 12 indexed citations
10.
Sheng, Yue, Chunjie Yu, Yin Liu, et al.. (2020). FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nature Communications. 11(1). 928–928. 67 indexed citations
11.
Hayashi, Yasutaka, Susumu Goyama, Shuhei Asada, et al.. (2019). Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nature Communications. 10(1). 4869–4869. 33 indexed citations
12.
Wunderlich, Mark, Nicole Manning, Anthony Sabulski, et al.. (2019). Improved chemotherapy modeling with RAG-based immune deficient mice. PLoS ONE. 14(11). e0225532–e0225532. 20 indexed citations
13.
Du, Wei, Wei Liu, Benjamin Mizukawa, et al.. (2018). A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells. Leukemia. 32(9). 2041–2046. 9 indexed citations
14.
Wunderlich, Mark, et al.. (2017). PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia. Blood. 130. 1318–1318. 1 indexed citations
15.
Goyama, Susumu, Mahesh Shrestha, Wendy R. Miller, et al.. (2016). Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Oncogene. 36(18). 2589–2598. 16 indexed citations
16.
Zhang, Shuangmin, Diamantis G. Konstantinidis, Jun‐Qi Yang, et al.. (2014). Gene Targeting RhoA Reveals Its Essential Role in Coordinating Mitochondrial Function and Thymocyte Development. The Journal of Immunology. 193(12). 5973–5982. 31 indexed citations
17.
Goyama, Susumu, Lea Cunningham, Yue Zhang, et al.. (2013). Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. Journal of Clinical Investigation. 123(9). 3876–3888. 151 indexed citations
18.
19.
Mizukawa, Benjamin, Jun-Ping Wei, Mahesh Shrestha, et al.. (2011). Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 118(19). 5235–5245. 53 indexed citations
20.
Mizukawa, Benjamin, Alex George, Suvarnamala Pushkaran, et al.. (2010). Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatric Blood & Cancer. 56(5). 840–842. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Munetake Shimabe Breakdown of academic impact, for papers by Wendy A. Hudson Breakdown of academic impact, for papers by Yuji Nakata Breakdown of academic impact, for papers by Cyril Šálek Breakdown of academic impact, for papers by Yasuhiko Kamikubo Breakdown of academic impact, for papers by Jesús Duque‐Afonso Breakdown of academic impact, for papers by Karsten Kratz‐Albers Breakdown of academic impact, for papers by Andrew Fong Breakdown of academic impact, for papers by Stephanie M. Dobson Breakdown of academic impact, for papers by R. Rossi
Rankless by CCL
2026